Lupin Limited has informed the Exchange regarding a press release dated January 16, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and RilpivirineTablets.".
Lupin Limited has informed the Exchange regarding a press release dated January 16, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and RilpivirineTablets.".